

Tackling Bioconjugate Challenges Virtual Summit 2026

Schedule

Thursday, 28 May, 2026

08:45-09:00

[CASSS Welcome & Virtual Summit Bioconjugates 2026 Introduction](#)

Presentation type: V - Virtual

09:00-10:20

[Session I - Control of Impurities](#)

Katie Duncan, Allison J Wolf

Presentation type: V - Virtual

Session Speakers:

Impurity Qualification Requirements for Drug-Linkers Related Impurities Used to Generate Antibody-Drug Conjugates

Osama Chahrour, *AstraZeneca*

Control of PMO-linker Impurities in Antibody-PMO Conjugates

Mitch Martini, *Avidity Biosciences, Inc.*

Managing Bioconjugate Heterogeneity Related to Drug-Linkers

Kevin Cole, *Eli Lilly and Company*

Charge Variant Control Strategy for Late-Stage Antibody Drug Conjugates

Carrie Sowers, *AstraZeneca*

10:20-10:35

[Break](#)

Presentation type: V - Virtual

10:35-12:05

[Session I Panel Discussion](#)

Katie Duncan, Allison J Wolf

Presentation type: V - Virtual

Additional Panelists:

Paresma (Pinky) Patel, *Gilead Sciences, Inc.*

Steffen Gross, *Paul-Ehrlich-Institut*

12:05-12:10

[Session I Summary & Closing Remarks](#)

Presentation type: V - Virtual

12:10-13:10

[Lunch Break](#)

Presentation type: V - Virtual

13:10-13:15

[CASSS Welcome & Virtual Summit Bioconjugates 2026 Introduction](#)

Presentation type: V - Virtual

13:15-14:35

Session II - Comparability

Hirendrasinh Parmar, Dawn Spiller

Presentation type: V - Virtual

Session Speakers:

CMC Regulatory Considerations for Antibody-Drug Conjugates (ADCs) – From the Biologics Perspective

Nailing Zhang, *CDER, FDA*

Analytical Comparability Approach for an Antibody Drug Conjugate

Tawnya Flick, *Gilead Sciences, Inc.*

Comparability Risk Mitigation: Identification of a New Low-Level Heavy-Heavy Chain Variant in an ADC

Yazhe Wang, *Merck & Co., Inc.*

Designing Risk-Based Analytical Comparability: Strategic Considerations for Antibody Drug Conjugates in Late-Phase Development

Qingyuan Liu, *AbbVie Inc.*

14:35-14:50

Break

Presentation type: V - Virtual

14:50-16:20

Session II Panel Discussion

Hirendrasinh Parmar, Dawn Spiller

Presentation type: V - Virtual

Additional Panelists:

Holly McCaleb, *Pfizer, Inc.*

Isha Nasa, *Health Canada*

16:20-16:30

Session II Summary & Concluding Remarks

Presentation type: V - Virtual